Neurocrine Biosciences | NBIX - Operating Profit


Neurocrine Biosciences reported $227.9M in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
AbbVie USD 5.81B 1.23B Dec/2025
Acadia Pharmaceuticals USD 17.39M 18.36M Dec/2025
Agios Pharmaceuticals USD -121.58M 4.71M Dec/2025
ALKERMES USD -10.95M 100.03M Dec/2025
Alnylam Pharmaceuticals USD 29.4M 59.36M Dec/2025
Amgen USD 3.96B 464M Dec/2025
Biogen USD 659.6M 192.2M Sep/2025
BioMarin Pharmaceutical USD 198.39M 230.08M Dec/2025
Cytokinetics USD -178.37M 11.61M Dec/2025
Enanta Pharmaceuticals USD -23.54M 98.15M Dec/2024
Exelixis USD 235.91M 20.45M Dec/2025
Gilead Sciences USD 2.96B 551M Dec/2025
Halozyme Therapeutics USD -88.41M 306.33M Dec/2025
Incyte USD 383.88M 47.43M Dec/2025
Ionis Pharmaceuticals USD -215M 54.82M Dec/2025
Nektar Therapeutics USD -34.34M 15.43M Sep/2024
Neurocrine Biosciences USD 227.9M 11.4M Dec/2025
Pfizer USD 4.65B 3.99B Dec/2025
Prothena USD -39.76M 12.25M Sep/2025
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Repligen USD 19.97M 7.29M Dec/2025
Rigel Pharmaceuticals USD 14.06M 13.61M Sep/2024
Sarepta Therapeutics USD -410.08M 347.2M Dec/2025
Teva Pharmaceutical Industries USD 487M 581M Dec/2025
Ultragenyx Pharmaceutical USD -114M 56.89M Dec/2025
Vertex Pharmaceuticals USD 1.26B 24.5M Dec/2025
Xoma USD -15.64M 5.56M Sep/2024